Drug Profile
Research programme: IKACh modulators - Xention
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Xention
- Class Small molecules
- Mechanism of Action Potassium channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atrial fibrillation
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Atrial-fibrillation in United Kingdom (PO)
- 25 Mar 2016 Preclinical development of IKACh modulators for the treatment of Atrial fibrillation is ongoing in the United Kingdom
- 12 Sep 2011 Preclinical trials in Atrial fibrillation in United Kingdom (PO)